Moderna’s melanoma win just lit a fire under the stock

A biotech plot twist, but make it market-moving

Moderna didn’t just get a good headline — it got the kind of Phase 3 readout that can send a stock into orbit. The company and Merck said their personalized mRNA cancer vaccine combo produced positive topline results in the INTerpath-001 trial, and MRNA jumped more than 100% on the news.

Why investors are suddenly paying attention

This is the first Phase 3 win for mRNA cancer therapy, which matters because biotech investors love two things: data and optionality. If a personalized cancer vaccine can actually keep melanoma from coming back, that’s a giant “maybe this platform is real” moment for Moderna.

Here’s the setup:

• The trial tested mRNA-4157, also called Intismeran autogene, alongside Merck’s Keytruda
• The study focused on patients with completely resected stage IIB-IV melanoma
• The headline readout centered on recurrence-free survival and distant metastasis-free survival

Merck gets a side quest, too

Merck isn’t just a name drop here. Keytruda is part of the combo, so the company gets pulled into the victory lap whether it wants the spotlight or not. And Moderna said the broader INTerpath program still includes a bunch of other cancer trials, which means today’s pop could be the opening scene, not the finale.

Big picture: biotech breakthroughs are usually more marathon than fireworks show. But when one of those marathons finally produces a sprint, the market notices — loudly.